Abstracts tagged "Biomarkers"

Abstract Number: 2104 • ACR Convergence 2024
The Relationship of Soluble Biomarkers to OA Pain: A Systematic Literature Review
Sylvain Mathieu¹, Liisa Kuhi², Philip G Conaghan³, Niels Eijkelkamp⁴, Yves Henrotin⁵, Eva Kosek⁶, Hans-George Schaible⁷, Ali Mobasheri⁸, Kalle Kisand⁹ and Jérémie Sellam¹⁰, and GO-PAIN working group, ¹CHU Gabriel Montpied, Clermont-Ferrand, France, ²East Tallinn Central Hospital, Tallinn, Estonia, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁴University Medical Center, Umtrecht, Netherlands, ⁵MusculoSkeletal Innovative research Lab (mSKIL), Liege, Belgium, ⁶Karolinska Institute, Stockholm, Sweden, ⁷Institute of Physiology, Jena, Germany, ⁸Research Unit of Medical Imaging, Physics and Technology, Ouli, Finland, ⁹University of Tartu, Tartu, Estonia, ¹⁰Saint-Antoine Hospital - AP-HP, Paris, Ile-de-France, France
Background/Purpose: Chronic joint pain is a major factor driving poor quality of life in people with osteoarthritis (OA). A better understanding of the complex mechanisms…
Abstract Number: 2366 • ACR Convergence 2024
Improvement in Pain-Associated Biomarkers with Deucravacitinib, a First-in-Class, Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Patients with PsA in a Double-Blind Phase 2 Study (IM011-084)
Philip Mease¹, Christopher Ritchlin², Lu Gao³, Peter Schafer⁴, Miroslawa Nowak³, Ian M. Catlett³ and Jinqi Liu³, ¹Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, ²Department of Medicine, Allergy, Immunology, and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY, ³Bristol Myers Squibb, Princeton, NJ, ⁴Bristol Myers Squibb, BELLE MEAD, NJ
Background/Purpose: Pain is a core domain of PsA, and reduction of pain is a primary treatment concern for patients with PsA. Pain has been reported…
Abstract Number: 2572 • ACR Convergence 2024
Biomarker-guided Treatment-and-stop-strategy for Recombinant IL-1Receptor Antagonist (Anakinra) in Patients with Systemic Juvenile Idiopathic Arthritis
Remco Erkens¹, Gerda Den Engelsman¹, Sytze De Roock¹, Dörte Hamann¹, Dieneke Schonenberg-Meinema², Merlijn van den Berg², Mariken Gruppen³, Wineke Armbrust⁴, Elizabeth Legger⁵, Sylvia Kamphuis⁶, Marleen Verkaaik⁷, Ellen Schatorjé⁸, Esther Hoppenreijs⁸, Thomas Vogl⁹, Johannes Roth⁹, Petra Hissink Muller¹⁰, Joost Swart¹, Marc Jansen¹, Jorg van Loosdregt¹¹ and Sebastiaan Vastert¹, ¹University Medical Center Utrecht, Utrecht, Netherlands, ²Amsterdam University Medical Center, Amsterdam, Netherlands, ³Amsterdam UMC, Amsterdam, Netherlands, ⁴University Medical Hospital Groningen, Groningen, Netherlands, ⁵University Medical Center Groningen, Groningen, Netherlands, ⁶Erasmus University Medical Center, Rotterdam, Netherlands, ⁷Erasmus Medical Center Rotterdam, Rotterdam, Netherlands, ⁸University Medical Center Radboud, Nijmegen, Nijmegen, Netherlands, ⁹University of Münster, Münster, Germany, ¹⁰Leiden University Medical Center, Leiden, Netherlands, ¹¹University Medical Center Utrecht, La Jolla, CA
Background/Purpose: Early initiation of treatment with the recombinant Interleukin 1 receptor antagonist (IL-1Ra), anakinra, in Still’s disease (SD), specifically systemic Juvenile Idiopathic Arthritis, patients is…
Abstract Number: 0270 • ACR Convergence 2024
Longitudinal Patterns of C-Reactive Protein Values in Calcium Pyrophosphate Deposition (CPPD) Disease
Muneet Gill, Hongshu Guan, Jamie Collins and Sara Tedeschi, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Calcium pyrophosphate deposition (CPPD) disease is a crystalline arthritis affecting older adults. Systemic inflammation occurs during flares of acute calcium pyrophosphate (CPP) crystal arthritis…
Abstract Number: 0468 • ACR Convergence 2024
Plasma Calprotectin Assessed in Multiple Biological Treatment Strategies for Early Rheumatoid Arthritis over 48 Weeks
David Stevens¹, Lene Sundbakk², Amirhossein Kazemi², Marte Heiberg³, Tuulikki Sokka-Isler⁴, Bjorn Gudbjornsson⁵, Kristina Lend⁶, Anna Rudin⁷, Michael Nurmohamed⁸, Jon Lampa⁹, Merete Hetland¹⁰, Mikkel Ostergaard¹¹, Ronald Van Vollenhoven¹², Tillmann Uhlig², Espen Haavardsholm² and Hilde Hammer³, ¹St. Olavs hospital, Trondheim, Norway, ²Diakonhjemmet Hospital, Oslo, Norway, ³Diakonhjemmet Hospital, Oslo, Oslo, Norway, ⁴University of Eastern Finland, Faculty of Health Sciences, Jyvaskyla, Finland, ⁵Landspitali University Hospital and University of Iceland, Reykjavik, Iceland, ⁶Amsterdam UMC, Karolinska Institute, Stockholm, Sweden, ⁷Institute of Medicine, University of Gothenburg, Gothenburg, Sweden, ⁸Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁹Karolinska University Hospital, Hässelby, Sweden, ¹⁰Rigshospitalet Glostrup and University of Copenhagen, Glostrup, Denmark, ¹¹Department of Clinical Medicine, University of Copenhagen and Center for Rheumatology, Copenhagen Center for Arthritis Research, Glostrup, Denmark, ¹²Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers, Amsterdam, Netherlands
Background/Purpose: Plasma calprotectin is a sensitive biomarker of inflammation in patients with rheumatoid arthritis (RA) and reflects activation of granulocytes and macrophages. Calprotectin has not…
Abstract Number: 0608 • ACR Convergence 2024
Systematic Analysis Demonstrates the Added Value of CB-CAPs to SLE Diagnosis in a Large Validation Cohort
Andrew Concoff¹, Touba Warsi², Sepehr Taghavi², Sudha Kumar², Abigail Patalinghug², Christine Schleif², Brittany Partain³, Joseph Ahearn⁴, Chau-Ching Liu⁵, Nicole Wilson⁵, Susan Manzi⁵ and Tyler O'Malley⁶, ¹Exagen, Inc., Los Angeles, CA, ²Exagen, Carlsbad, CA, ³Exagen, Boston, MA, ⁴Allegheny Health Network, Wexford, PA, ⁵Allegheny Health Network, Pittsburgh, PA, ⁶Exagen, Vista, CA
Background/Purpose: Cell bound complement activation products (CB-CAPs) including erythrocyte-bound C4d (EC4d) and B-lymphocyte C4d (BC4d) demonstrate increased diagnostic accuracy compared to conventional SLE markers (anti-dsDNA,…
Abstract Number: 0713 • ACR Convergence 2024
Anti-muscarinic 3 Antibodies in SSc Associate with a More Significant GI and Extraintestinal Clinical Phenotype
Naveen Kalavar¹, Michael Hughes², Walter Morales³, Ami Shah⁴, Elizabeth Volkmann⁵, Roshan Dongre⁶, Mark Pimentel⁷, Laura Hummers⁸ and Zsuzsanna McMahan⁹, ¹University of Texas Health Science Center, Houston, TX, ²University of Manchester, Manchester, United Kingdom, ³Cedars-Sinai, Los Angeles, CA, ⁴Division of Rheumatology, Johns Hopkins University, Ellicott City, MD, ⁵University of California, Department of Medicine, Los Angeles, CA, USA, Los Angeles, ⁶Methodist Hospital, Houston, TX, ⁷Cedars-Sinai, Los Angeles, ⁸Johns Hopkins University, Division of Rheumatology, Baltimore, MD, Ellicott City, MD, ⁹UTHealth Houston Division of Rheumatology, Houston, TX
Background/Purpose: Systemic sclerosis (SSc) is a complex autoimmune connective tissue disease that negatively impacts internal organ function, including the gastrointestinal tract. While the etiology of…
Abstract Number: 0862 • ACR Convergence 2024
Two-year’s Worsening of Semi-quantitative MRI Features as Surrogate Outcomes for Long-term Incident Radiographic Knee Osteoarthritis After ACL-rupture
Jos Runhaar¹, Belle van Meer², Vernon Smit¹, mauro minnaard¹, Edwin Oei¹, Max Reijman¹ and Duncan Meuffels¹, ¹Erasmus MC University Medical Center Rotterdam, Rotterdam, Netherlands, ²St. Antonius Hospital Utrecht, Department of Sports Medicine, Utrecht, Netherlands
Background/Purpose: With an annual incidence rate of 2-5% in high-risk populations, the use of established knee OA as an outcome challenges the feasibility of preventive…
Abstract Number: 1105 • ACR Convergence 2024
PDGFA and TGFB1, Key Genes to Discriminate Autoimmune Diseases-Related Interstitial Lung Disease from Idiopathic Pulmonary Fibrosis?
Veronica Pulito-Cueto¹, Belén Atienza-Mateo², David Iturbe-Fernández³, Victor M. Mora-Cuesta³, Joao Carlos Batista-Liz¹, María Sebastián Mora-Gil⁴, José M. Cifrián⁵, Ricardo Blanco-Alonso⁶ and Raquel Lopez-mejias¹, ¹IDIVAL, Santander, Spain, ²Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Cantabria, Spain, ³Immunopathology Group, Valdecilla Research Institute (IDIVAL) and Department of Pneumology, Marqués de Valdecilla University Hospital (HUMV), Santander, ⁴Immunopathology Group, Valdecilla Research Institute (IDIVAL) and Department of Rheumatology, Marqués de Valdecilla University Hospital (HUMV), Santander, ⁵Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. Immunopathology group, IDIVAL, Santander, ⁶Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: Interstitial lung disease (ILD) constitutes one of the main causes of mortality in patients with autoimmune diseases (ADs) [1]. The early diagnosis of AD-ILD+…
Abstract Number: 1330 • ACR Convergence 2024
Increased Levels of F-calprotectin in Patients with Early Rheumatoid Arthritis at Diagnosis
Jon Einarsson¹, Katarina Friberger Pajalic², Caroline Bengtsson³, Carmen Roseman⁴, Ellen Landgren¹, Elisabeth Mogard⁵, Elisabet Lindqvist⁵, Tor Olofsson⁴, Johan Karlsson Wallman⁶ and Meliha C Kapetanovic⁴, and Lund Arthritis Research Group (LARG), ¹Lund University, Department of Clinical Sciences Lund, section of rheumatology and Skåne University Hospital Lund, Sweden, Lund, Skane Lan, Sweden, ²Lunds University, Department of clinical sciences, section of Rheumatology Malmö and Skåne University Hospital Malmö, Sweden, Malmö, Sweden, ³Skåne University Hospital Lund, Sweden, Lund, Sweden, ⁴Lund University, Department of Clinical Sciences Lund, section of rheumatology and Skåne University Hospital Lund, Sweden, Lund, Sweden, ⁵Lund University, Department of Clinical Sciences Lund, Section of Rheumatology and Skåne University Hospital, Lund, Sweden, Lund, Sweden, ⁶Lund University, Department of Clinical Sciences Lund, Section of Rheumatology and Skåne University Hospital, Lund, Sweden, Lund, Skane Lan, Sweden
Background/Purpose: Alterations in gut microbiota (dysbiosis) may contribute to the development of rheumatoid arthritis (RA). Elevated fecal calprotectin (F-calprotectin), an established biomarker of gut inflammation, has…
Abstract Number: 1581 • ACR Convergence 2024
Neutrophil-to- lymphocyte Ratio: A Possible Biomarker for Clinical Response After Autologous Hematopoietic Stem Cell Transplantation
shiri keret¹, Lisa Kaly², Georg Schett³, Christina Bergmann⁴, Joerg Henes⁵, Gleb Slobodin² and Doron Rimar², ¹Rheumatology unit, Bnai-Zion medical center and the faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel., Atlit, Israel, ²Rheumatology unit, Bnai-Zion medical center and the faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel., Haifa, Israel, ³Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, ⁴Department Internal Medicine III, Friedrich-Alexander-University (FAU) Erlangen-Nurnber, Frankfurt, Germany, ⁵University Hospital Tuebingen, Tuebingen, Germany
Background/Purpose: Baseline high Neutrophil- to- lymphocyte ratio (NLR) (higher than 2.95) is associated with severe progressive skin and lung disease and with reduced 5-year survival…
Abstract Number: 1812 • ACR Convergence 2024
Glycosylation Changes as Non-Invasive Biomarkers for Lupus Nephritis Detection and Prognosis
Aaron Angerstein¹, Richard Drake², Vishwajeeth Pasham², Bethany Wolf², Jim Oates² and Tammy Nowling², ¹Medical University of South Carolina, North Charleston, SC, ²Medical University of South Carolina, Charleston, SC
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease predominantly affecting women of childbearing age. Roughly 50% of SLE patients develop Lupus Nephritis (LN),…
Abstract Number: 2117 • ACR Convergence 2024
The Risk of Medication-related Osteonecrosis of the Jaw (MRONJ) in a Patient with Osteoporosis Treated with Antiresorptive Therapy and Undergoing Dental Care Is Negligible with a CTX Threshold Above 260
Camille Ghio, Robinson Gravier-Dumonceau, Pierre Lafforgue, Roch Giorgi and Thao Pham, Assistance Publique-Hôpitaux de Marseille, Marseille, France
Background/Purpose: Although antiresorptive treatments, including bisphosphonates and denosumab, have demonstrated their efficacy in treating osteoporosis. However, osteonecrosis of the jaw has been reported as a…
Abstract Number: 2382 • ACR Convergence 2024
Utility of Urinary Biomarkers to Predict Long-term Renal Outcomes in Lupus Nephritis
Ryan Baker¹, Laura Patricia Whittall Garcia¹, Michael Kim¹, Dennisse Bonilla¹, Murray Urowitz², Dafna Gladman³, Zahi Touma⁴ and Joan Wither¹, ¹University Health Network, Toronto, ON, Canada, ²Self employed, Toronto, ON, Canada, ³University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada
Background/Purpose: Lupus nephritis (LN) affects up to 50% of patients with Systemic Lupus Erythematosus. Around 40% of patients will experience a subsequent renal flare in…
Abstract Number: 2574 • ACR Convergence 2024
Tear Biomarkers for Monitoring Disease Activity and Progression of Noninfectious Chronic Anterior Uveitis in Children
Mariia Pavlenko¹, Ilaria Maccora², Mekibib Altaye³, hermine brunner⁴, Alexandra Duell³, Megan Quinlan-Waters³, Alyssa Sproles¹, Sherry Thornton⁵, Virginia Miraldi Utz³ and sheila Angeles-Han⁶, ¹Division of Rheumatology, Cincinnati Children`s Hospital Medical Center, Cincinnati, OH, ²?PhD student, in the Area of Drugs and Innovative Treatments, NeuroFARBA Department, University of Florence. Meyer Children's Hospital, Florence Italy, Firenze, Florence, Italy, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, ⁵Cincinnati Children's Hospital, Cincinnati, ⁶Cincinnati Children's Hospital, Cincinnati, OH
Background/Purpose: Childhood chronic anterior uveitis (CAU) can be idiopathic (iCAU) or associated with Juvenile Idiopathic Arthritis (JIA-U). Ocular complications occur in 50% of affected children. …

« Previous Page
1
…
3
4
5
6
7
…
96
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].